UnitedHealth's Promises in Public, Opacity in Practice:

UnitedHealth's massive growth just got harder to track | STAT

Health System Accountability Report

Investigative Health Policy & Corporate Transparency

Corporate Transparency & Accountability

UnitedHealth Slashes Subsidiary Disclosures Even as It Pledges Transparency

As CEO Stephen Hemsley vows a new era of openness and regulators circle, America's largest health care conglomerate quietly reduced the number of subsidiaries disclosed in its annual SEC filing from nearly 3,100 to just 10.

When UnitedHealth Group filed its annual report with the Securities and Exchange Commission this week, observers who know where to look noticed something remarkable — and troubling. The Exhibit 21 attachment, which lists a corporation's subsidiaries, identified just 10 entities within the sprawling health care empire. One year ago, the same exhibit named nearly 3,100.

The dramatic reduction in disclosed subsidiaries runs directly counter to a string of high-profile pledges from UnitedHealth's leadership to increase transparency, reform corporate governance, and rebuild the public's battered trust. Coming at a moment when the company faces active Department of Justice investigations, congressional scrutiny, a landmark cyber-security breach, and historic reputational damage, the move raises urgent questions about whether the company's reform commitments are substantive or purely cosmetic.

UnitedHealth Group — Key Figures at a Glance

Subsidiaries disclosed in 2025 annual report (Exhibit 21)~3,100

Subsidiaries disclosed in 2026 annual report (Exhibit 21)10

2025 consolidated revenues$447.6 billion

People served by UnitedHealthcare (2025)49.8 million

Physicians owned or affiliated through Optum90,000+

UNH stock decline, year-to-date through end of 2025~40%

Data breach (Change Healthcare) — individuals affected190 million

The Disclosure That Disappeared

SEC rules require publicly traded companies to file a list of their subsidiaries as part of their annual 10-K report — Regulation S-K, Item 601(b)(21). The longstanding regulatory intent is to give investors, regulators, and the public visibility into the corporate family of entities that constitute a major company. Companies are required to list all subsidiaries except those that, in the aggregate, would not constitute a "significant subsidiary" as defined by SEC Rule 1-02(w) of Regulation S-X.

UnitedHealth had historically provided an expansive view. Its 2025 Exhibit 21 ran to nearly 3,100 named entities — a reflection of the extraordinary web of insurance plans, physician group practices, data analytics firms, pharmacy benefit operations, clinics, and specialty care providers assembled over decades of acquisition. The 2026 version lists just 10, with no public explanation for the drastic change.

The reduction does not mean UnitedHealth shed thousands of subsidiaries — the company's revenues, headcount, and market operations show no such contraction. Instead, the company appears to have exercised maximum legal latitude to omit the vast majority of entities from public disclosure, apparently concluding that they do not, in the aggregate, meet the "significant subsidiary" threshold required by the rule — a threshold that critics have long argued is too easily met by large conglomerates that can obscure subsidiaries across layers of holding companies.

The practical effect is to conceal the reach of a company that, by most measures, touches nearly every corner of American health care. UnitedHealth Group encompasses UnitedHealthcare (the nation's largest private insurer), Optum (which includes physician practices, pharmacy benefit management via OptumRx, data and analytics through OptumInsight, and care delivery through OptumHealth), Change Healthcare (a claims processing and health IT giant), and dozens of regional plans, specialty companies, and international businesses.

The far more limited disclosure hides the scope of its sprawling network of businesses that includes insurance, medical clinics, and pharmacies — at precisely the moment regulators and the public are demanding to understand it better.

A Cascade of Crises

The disclosure change comes after eighteen months that have been, by any measure, the most turbulent in UnitedHealth's history. Understanding the full context requires tracing a series of overlapping crises that have placed the company under extraordinary scrutiny.

On December 4, 2024, Brian Thompson, the chief executive of UnitedHealthcare — the insurance arm of UnitedHealth Group — was shot and killed outside a Manhattan hotel as he arrived for the company's annual investor conference. His alleged killer, Luigi Mangione, left behind writings expressing fury at the health insurance industry. The words "delay," "deny," and "depose" were reportedly inscribed on shell casings found at the scene — a direct allusion to the insurance industry's tactic of delaying, denying, and defending against claims. Mangione pleaded not guilty to both state and federal charges, and legal proceedings continue.

The killing catalyzed what amounted to a national reckoning. Social media erupted with millions of posts describing personal experiences with claim denials, prior authorization delays, and coverage disputes with UnitedHealthcare and the broader insurance industry. A December 2024 NORC at the University of Chicago poll found that most American adults believed health insurance companies' denial practices bore at least moderate responsibility for the atmosphere that led to Thompson's death. UnitedHealthcare had long maintained one of the higher claim denial rates in the industry, and the company faced a class action lawsuit — filed before Thompson's death — alleging it used artificial intelligence to automatically deny Medicare Advantage prior authorization requests at a rate that critics said was indefensible.

The reputational damage was compounded by the financial. In February 2025, the Wall Street Journal reported that the Department of Justice had launched a civil fraud investigation into UnitedHealth's Medicare Advantage billing practices — specifically, allegations that the company had been systematically "upcoding" patient diagnoses to generate larger government payments. The DOJ investigation, working alongside the FBI and HHS Office of Inspector General, was confirmed by UnitedHealth in a formal SEC filing in July 2025, sending the stock down another 4–5 percent.

Separately, the DOJ had been investigating UnitedHealth's Optum subsidiary for potential antitrust violations — specifically, whether Optum's aggressive acquisition of physician practices, and the potential for UnitedHealthcare to favor Optum-owned providers, was harming competition. Senators Elizabeth Warren and Edward Markey further urged the SEC to open an insider trading investigation after Bloomberg reported that four top UnitedHealth executives — including then-Chairman Stephen Hemsley — sold a combined $101.5 million in company stock in the months after learning of the DOJ antitrust investigation but before it became public knowledge.

In January 2025, UnitedHealth disclosed that the February 2024 cyberattack on its Change Healthcare subsidiary had compromised the protected health information of approximately 190 million people — making it the largest health care data breach in American history. The company has paid more than $3 billion to health care providers affected by the disruption to claim processing systems.

The Transparency Pledge — and What Followed

On May 13, 2025, CEO Andrew Witty resigned "for personal reasons," effective immediately. The board reinstated Stephen Hemsley, who had served as CEO from 2006 to 2017 and was credited with building UnitedHealth into the conglomerate it became. On the investor transition call, Hemsley apologized for the company's performance difficulties and promised a new chapter. "I'm deeply disappointed in, and apologize for, the performance setbacks we have encountered," he said. "Many of the issues standing in the way of achieving our goals are largely within our control. I am optimistic about our future."

Hemsley followed up with a series of governance and transparency initiatives. In August 2025, UnitedHealth announced the formation of a "Public Responsibility Committee" within its board of directors, charged with monitoring financial, regulatory, and reputational risks — including oversight of prior authorization policies, the business practices of Optum Rx, and the company's use of artificial intelligence in claims processing. Board member Michele Hooper was named chair of the committee.

In late 2025, Hemsley commissioned independent audits by FTI Consulting and the Analysis Group of UnitedHealth's Medicare Advantage risk coding practices, utilization management and prior authorization processes, and Optum Rx's handling of manufacturer discounts. The results, released in December 2025, found no "smoking gun" of deliberate misconduct but identified numerous deficiencies in policy documentation, governance structures, and audit remediation. UnitedHealth adopted 23 "action plans" in response, promising 65 percent completion by year-end 2025 and full implementation by March 31, 2026.

In January 2026, Hemsley testified before two House committees on health care affordability. His prepared testimony described a company "intensely focused on setting a new standard of transparency, simplicity, and ongoing improvement." He pledged operational reforms and offered data on the cost of hospital consolidation as a driver of rising health care expenditures — an argument widely seen by critics as an attempt to deflect blame for insurer practices onto hospital systems.

February 2024

Cyberattack on Change Healthcare disrupts billing nationwide; ultimately affects 190 million individuals' personal health data — the largest U.S. health care breach on record.

February–October 2024

DOJ antitrust investigation of UnitedHealth/Optum reported; four executives sell $101.5 million in stock before public disclosure; Senators Warren and Markey urge SEC investigation for insider trading.

December 4, 2024

UnitedHealthcare CEO Brian Thompson shot and killed outside New York hotel. Luigi Mangione arrested; pleads not guilty to state and federal charges. National outrage over claim denial practices erupts.

February 2025

DOJ civil fraud investigation of Medicare Advantage billing practices reported. UnitedHealth offers employee buyouts, signals potential layoffs. Company denies wrongdoing.

April–May 2025

UnitedHealth posts rare earnings miss; slashes 2025 guidance; stock drops 22% in single day, wiping $100+ billion in market value. CEO Andrew Witty resigns; Stephen Hemsley returns as CEO.

July 2025

UnitedHealth confirms in SEC filing it is under DOJ criminal and civil investigation regarding Medicare Advantage. Stock drops again. Hemsley pledges transparent relationship with regulators and public.

August 2025

UnitedHealth forms "Public Responsibility Committee" on its board. Activist investor group simultaneously calls for splitting the CEO and board chair roles, citing governance concerns.

December 2025

Independent audits by FTI Consulting and Analysis Group released; 23 action plans adopted. Hemsley describes commitment to "new standard of transparency." Stock still down ~40% year-to-date.

January 2026

Hemsley testifies before two House committees, pledging transparency and reform. Critics characterize the testimony as a PR maneuver before a politically charged congressional hearing.

March 2026

UnitedHealth files 2025 annual report with SEC. Exhibit 21 lists just 10 subsidiaries — down from nearly 3,100 the previous year. No public explanation offered. STAT News first reports the rollback.

The Opacity Critics Said Was Always There

For years before the current crisis, health policy researchers and antitrust advocates had warned that UnitedHealth's sheer complexity — the interlocking relationships between its insurance, provider, pharmacy benefit, and technology businesses — made it effectively impossible for regulators, competitors, or patients to understand how it operates and whether it is exploiting market power to foreclose competition.

The DOJ antitrust investigation zeroed in on a central concern: whether UnitedHealthcare, the insurer, systematically favored Optum, the provider and pharmacy benefit arm, in ways that harmed other physicians and health systems. Investigators asked whether UnitedHealthcare directed members to Optum-owned facilities, offered Optum providers superior contract rates, or withheld network access from competing insurers. Optum's footprint — with more than 90,000 owned or affiliated physicians — makes it among the largest physician employers in the country, operating largely beneath the public radar.

A nonprofit coalition of California hospitals and physicians separately filed a civil lawsuit alleging that UnitedHealth used its market power to prevent them from competing for primary care physicians. And a Senate Finance Committee report issued in October 2024 documented UnitedHealth's aggressive — and, the senators argued, inappropriate — pursuit of higher Medicare Advantage payments through risk adjustment coding that critics characterized as systematic upcoding.

Analysts who reviewed UnitedHealth's revenue composition noted a striking figure: between 2020 and 2024, approximately 74 percent of the company's revenue came from taxpayers — through Medicare Advantage, Medicaid managed care, and other government programs. This raises the question of whether a company so deeply reliant on public dollars owes the public a clearer accounting of its internal structure.

Critics also pointed to a pattern of legal aggression toward those who scrutinize the company. Reports from 2025 revealed that UnitedHealth had sued multiple media outlets and social media users over allegedly defamatory coverage, including The Guardian over investigations into its management of nursing home transfers and a physician who went viral describing a claim denial during a surgical procedure. The lawsuits were widely seen as an attempt to chill critical reporting.

Is the Subsidiary Reduction Legal?

The SEC does not require companies to list every subsidiary — only those that collectively would constitute a "significant subsidiary" under the relevant regulation. Companies have long used this flexibility to limit Exhibit 21 disclosures, and UnitedHealth's legal team almost certainly concluded that the 2026 reduction was defensible under current rules.

However, the spirit of the disclosure requirement is to give the public meaningful insight into a registrant's corporate family. The SEC has noted in guidance that companies should list subsidiaries that are meaningful to understanding the registrant's business, even if they do not technically meet the quantitative threshold for "significant subsidiary." Given UnitedHealth's extraordinary scale and the number of investigations into the conduct of its subsidiary network, the decision to provide only minimal disclosure invites serious questions about intent.

Former SEC enforcement officials and securities law scholars have noted that companies sometimes reduce subsidiary disclosures when they are under investigation, both to limit the roadmap available to investigators and to reduce the public profile of entities that might attract regulatory attention. UnitedHealth has not offered any public explanation for the change.

Institutional Response and Congressional Scrutiny

UnitedHealth faces a constellation of ongoing government and legal actions. The DOJ's Medicare fraud investigation remains active, with the company cooperating through formal criminal and civil requests. The DOJ antitrust probe into Optum Rx is also ongoing. Congressional committees on both sides of the aisle have expressed interest in the company's practices, and President Trump has publicly criticized health insurers for high premiums and denied care — a striking development given the historical political alignment between Republicans and large private health plans.

The Accountability Board, an activist investor group, filed a formal shareholder proposal in October 2025 calling on UnitedHealth to separate the CEO and board chair roles — arguing that Stephen Hemsley's dual position as both CEO and board chairman "undercut the board's traditional checks and balances." The proposal points to UnitedHealth's own Corporate Governance Principles, issued just months before Hemsley was named to both roles simultaneously, which explicitly called for those roles to be kept separate.

On the litigation front, a proposed securities class action lawsuit filed in the Southern District of New York alleges that UnitedHealth misled investors by failing to disclose the financial and reputational impact of the public backlash following Thompson's killing, artificially sustaining an earnings forecast that the company internally knew was unrealistic. The case, brought by investor Roberto Faller, is pending class certification.

What the Subsidiary Rollback Means for Patients and the Public

The reduction in disclosed subsidiaries may seem like an arcane accounting matter, but its implications are material for patients, providers, and policymakers. Understanding which entities are affiliated with UnitedHealth is essential for physicians trying to understand network relationships, for state insurance regulators tracking capital adequacy, for antitrust investigators mapping competitive relationships, and for patients trying to understand who is making decisions about their care.

When a patient's claim is denied by a company they have never heard of, when a physician is paid through an Optum subsidiary with an unfamiliar name, when a pharmacy benefit manager negotiates drug prices through a shell of affiliated entities — the subsidiary list is one of the few public windows into the corporate structure behind those transactions. Reducing it by 99.7 percent closes that window nearly entirely.

For the Informed Prostate Cancer Support Group and other patient advocacy organizations, the subsidiary rollback is particularly concerning because UnitedHealth's sprawling corporate structure directly affects how Medicare Advantage plans handle coverage for advanced cancer treatments — including PSMA-targeted therapies, Pluvicto, and emerging treatments under clinical investigation. Patients denied care or struggling to understand their coverage are now further from being able to identify who within the UnitedHealth corporate family is making those decisions.

UnitedHealth did not respond to requests for comment on the subsidiary disclosure reduction as of publication time.

When a company that controls nearly 74 percent of its revenue from government programs simultaneously pledges transparency and eliminates 99.7 percent of its subsidiary disclosures, the contradiction speaks loudly on its own.

Conclusion

The arithmetic of UnitedHealth's subsidiary disclosure is stark: 3,100 entities reduced to 10, in the same year that its CEO testified before Congress about setting "a new standard of transparency," its board formed a "public responsibility committee," and its independent auditors urged it to centralize and codify its compliance and governance processes.

Whether the rollback reflects a defensible legal judgment, a deliberate strategy to limit regulatory roadmaps, or both, the signal it sends is unmistakable. For a company that has spent the better part of eighteen months telling the public — and lawmakers, and regulators — that it is committed to a new era of openness, the decision to provide minimum-legally-required visibility into its corporate structure represents a significant and conspicuous contradiction.

The coming months will test whether UnitedHealth's commitments to transparency are real or rhetorical. The DOJ investigations continue. Congressional oversight intensifies. The independent audits' 23 action plans are due for completion. The shareholder litigation proceeds. And observers who know where to look in the SEC's EDGAR database will be watching the next Exhibit 21 very closely.

Compiled from investigative sources March 5, 2026 Based on reporting by STAT News, Healthcare Dive, CNBC, Reuters, NPR, and SEC filings

Editor's Note: This article synthesizes reporting from multiple outlets, SEC filings, court documents, congressional testimony, and independent research as of March 5, 2026. The primary disclosure finding was first reported by Bob Herman of STAT News on March 4, 2026.

 

Sources and Formal Citations

[1] Herman, Bob. "UnitedHealth promised transparency. Instead, it's cutting back key disclosures." STAT News, March 4, 2026.
https://www.statnews.com/2026/03/04/unitedhealth-limits-subsidiary-disclosure-sec-reporting-shift/

[2] UnitedHealth Group, Inc. Form 10-K Annual Report (FY 2025), filed with the U.S. Securities and Exchange Commission, March 2, 2026. Accession No. 0000731766-26-000062.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000731766&type=10-K

[3] UnitedHealth Group, Inc. Form 10-K Annual Report (FY 2024), filed with the U.S. Securities and Exchange Commission, February 2025. Exhibit 21.1 — Subsidiaries of UnitedHealth Group Incorporated.
https://www.unitedhealthgroup.com/content/dam/UHG/PDF/investors/2024/UNH-Q4-2024-Form-10-K.pdf

[4] Pifer Parduhn, Rebecca. "UnitedHealth forms new 'public responsibility' board committee." Healthcare Dive, August 21, 2025.
https://www.healthcaredive.com/news/unitedhealth-board-committee-reputational-regulatory-risks/758246/

[5] Pifer Parduhn, Rebecca. "UnitedHealth commits to changes after independent review." Healthcare Dive, December 22, 2025.
https://www.healthcaredive.com/news/unitedhealth-independent-review-results-pledges-reform/808474/

[6] Pifer Parduhn, Rebecca. "Shareholder group calls on UnitedHealth to decouple CEO from board chair." Healthcare Dive, October 6, 2025.
https://www.healthcaredive.com/news/unitedhealth-separate-ceo-board-chair-accountability-board-proposal/802003/

[7] Pifer Parduhn, Rebecca. "UnitedHealth confirms it's under investigation by DOJ." Healthcare Dive, July 24, 2025.
https://www.healthcaredive.com/news/unitedhealth-under-investigation-department-of-justice-medicare/753913/

[8] Pifer Parduhn, Rebecca. "UnitedHealth under antitrust investigation by DOJ: reports." Healthcare Dive, February 28, 2024.
https://www.healthcaredive.com/news/unitedhealth-antitrust-investigation-doj-unitedhealthcare-optum/708727/

[9] Roy, Sneha. "UnitedHealth CEO Andrew Witty steps down, company suspends annual forecast." Reuters/CNBC, May 13, 2025.
https://www.cnbc.com/2025/05/13/unitedhealth-group-ceo-andrew-witty-steps-down.html

[10] Famakinwa, Joyce. "UnitedHealth Group CEO Andrew Witty Steps Down, Company Suspends 2025 Financial Forecast." Home Health Care News, May 13, 2025.
https://homehealthcarenews.com/2025/05/unitedhealth-group-ceo-andrew-witty-steps-down-company-suspends-2025-financial-forecast/

[11] Famakinwa, Joyce. "UnitedHealth Group CEO Andrew Witty Steps Down." Fierce Healthcare, May 13, 2025.
https://www.fiercehealthcare.com/payers/unitedhealth-group-suspends-2025-outlook-ceo-andrew-witty-steps-down

[12] "DOJ investigation of UnitedHealth confirmed in SEC filing." HealthExec, August 18, 2025.
https://healthexec.com/topics/healthcare-management/legal-news/doj-investigation-unitedhealth-confirmed-sec-filing

[13] UnitedHealth Group. "UnitedHealth Group Responds to Department of Justice Investigation." UnitedHealth Group Newsroom, July 24, 2025.
https://www.unitedhealthgroup.com/newsroom/2025/2025-07-24-uhg-responds-to-doj-investigation.html

[14] "Killing of Brian Thompson." Wikipedia, continuously updated. Cited for polling data and contemporaneous social media analysis.
https://en.wikipedia.org/wiki/Killing_of_Brian_Thompson

[15] Lovelace, Berkeley Jr. "Killing of health insurance CEO draws attention to frustration over denied claims." NBC News, December 11, 2024.
https://www.nbcnews.com/health/health-news/ceo-shooting-health-insurance-frustration-denied-claims-rcna183805

[16] Faller v. UnitedHealth Group, Inc., proposed class action complaint, S.D.N.Y., May 2025. Reported by CBS News.
https://www.cbsnews.com/news/unitedhealth-investors-lawsuit-brian-thompson-luigi-mangione/

[17] Warren, Elizabeth; Markey, Edward J.; Auchincloss, Jake et al. Letter to SEC Chair Gary Gensler urging insider trading investigation. U.S. Senate Press Release, 2024.
https://www.warren.senate.gov/newsroom/press-releases/warren-markey-auchincloss-and-13-house-members-urge-sec-to-open-investigation-into-unitedhealth-executives-insider-trading-concerns

[18] Hemsley, Stephen J. Prepared Testimony before the House Ways and Means Committee and Energy and Commerce Committee, January 22, 2026.
https://waysandmeans.house.gov/wp-content/uploads/2026/01/UnitedHealth-Group-Testimony-of-Stephen-J.-Hemsley-WM.pdf

[19] Potter, Wendell. "UnitedHealth Group Throws a Hail Mary Before CEO Testifies." Health Care un-covered (Substack), January 22, 2026.
https://healthcareuncovered.substack.com/p/unitedhealth-group-throws-a-hail

[20] "UnitedHealth releases companywide policy audit report: 10 things to know." Becker's Payer Issues, December 2025.
https://www.beckerspayer.com/research-analysis/unitedhealth-releases-company-wide-policy-audit-report-10-things-to-know/

[21] "UnitedHealthcare Is Struggling To Recover From Luigi Mangione." Newsweek, June 5, 2025.
https://www.newsweek.com/unitedhealthcare-struggling-recover-luigi-mangione-2073305

[22] U.S. Securities and Exchange Commission. Regulation S-K, Item 601(b)(21) — Subsidiaries of the registrant; and Regulation S-X, Rule 1-02(w) — Significant subsidiary definition.
https://www.ecfr.gov/current/title-17/chapter-II/part-229/subpart-229.600/section-229.601

[23] "UnitedHealth Group abruptly replaces CEO Andrew Witty, deepening a terrible year." NPR, May 13, 2025.
https://www.npr.org/2025/05/13/nx-s1-5396614/unitedhealth-group-terrible-year-replaces-ceo-andrew-witty

[24] Lovelace, Berkeley Jr. "Insurers promised to ease a major patient pain point after executive's murder. Here's what's happened." CNN, December 5, 2025.
https://www.cnn.com/2025/12/04/health/insurers-prior-authorization-unitedhealthcare-ceo

[25] UnitedHealth Group, Inc. 8-K filing disclosing DOJ investigation, filed with the SEC, August 14, 2025.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000731766&type=8-K